Micreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance
Zug, Switzerland (ots/PRNewswire) - In a new publication, the company's flagship compound proves effective in targeting the harmful pathogen while preserving a healthy microbiome Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in ...